FIGURE 3.

The CBD and CID160 administered in the GPe generated superior forelimb performance in the staircase test. The number of pellets eaten, the number of pellets taken, and the percentage of grasping success were recorded on the 19th day post-lesion. The GPR55r agonist LPI (10 µM) (A–C), the inverse agonist CBD (10 µM) (D–F), and the selective antagonist CID160 10 µM (G–I) were administered via intrapallidal injection on the 30th day. It is shown that the 6-OHDA + CBD and 6-OHDA + CID160 groups increase the indices of motor performance in contrast with the 6-OHDA + LPI and 6-OHDA + DMSO groups. Data are represented as group mean ± SEM. ^*** p < 0.001 vs. vehicle; ⁺ p < 0.05, ⁺⁺ p < 0.01, ⁺⁺⁺ p < 0.001 vs. vehicle + DMSO 0.01%; ^# p < 0.05, ^### p < 0.001 vs. 6-OHDA + DMSO 0.01%; a one-way ANOVA followed by a Tukey post-hoc test, (n = 5–7/group).